A Phase I Dose-Escalation Study of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors
A Phase I, First-In-Human, Open-Label, Multicenter, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors
CUG279-P101 is a first-in-human, open-label, multicenter Phase 1 study evaluating the safety, tolerability, pharmacokinetics, immunogenicity, immune-pharmacodynamics, and preliminary antitumor activity of CUG279 in adults with select unresectable advanced or metastatic solid tumors.
研究概览
详细说明
The study will consist of two parts: Part A Dose Escalation and Part B Dose Expansion
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Admin Cugene
- 电话号码:1(781) 893-5800
- 邮箱:admin@cugene.com
学习地点
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- 招聘中
- NEXT Virginia
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Signed and dated informed consent.
- Histologically or cytologically confirmed selected locally advanced or metastatic solid tumor.
- At least 1 measurable lesion according to RECIST v1.1.
- Progressed after, intolerant to, declined, or not considered a candidate for available standard-of-care (SoC) therapy.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Adequate cardiovascular, hematologic, renal, hepatic, and coagulation function.
- Life expectancy of ≥3 months.
- Female participants must not be pregnant or breastfeeding. Male participants with female partners of childbearing potential must agree to use effective contraception as specified in the protocol.
Exclusion Criteria
- Rapidly progressing disease or disease requiring urgent alternative medical intervention.
- Recent or concurrent malignancy, except certain adequately treated or low-risk malignancies as specified in the protocol.
- Prior anticancer, investigational, radiation, or immunomodulatory therapy within protocol-specified washout periods, or prior IL-2/IL-15-based therapy.
- Concurrent participation in another interventional therapeutic clinical trial.
- Active or clinically significant CNS disease, including symptomatic CNS metastases or leptomeningeal disease, except as specified in the protocol.
- Clinically significant autoimmune disease, immunodeficiency, requirement for systemic immunosuppressive therapy, or history of severe immune-mediated adverse events.
- Unresolved clinically significant toxicities from prior anticancer therapy.
- Clinically significant cardiovascular, thromboembolic, pulmonary, hepatic, or gastrointestinal disease.
- Active or clinically significant infection except as specified in the protocol.
- Recent major surgery or trauma, or prior allogeneic hematopoietic stem cell, bone marrow, or solid organ transplantation.
- Known hypersensitivity or significant allergic reaction to biologics or its components.
- Recent vaccination, except as permitted by the protocol.
- Any medical, psychological, social, or other condition that, in the Investigator's opinion, may increase risk, interfere with study participation, or confound interpretation of study results
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part A Dose Escalation
CUG279 will be administered at multiple ascending dose levels |
CUG279 will be administered intravenously according to the protocol |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of dose limiting toxicities (DLTs)
大体时间:From the first dose up to 21 days post-dose
|
The number and percentage of participants with DLTs will be assessed according to the protocol-specified DLT criteria in Part A. |
From the first dose up to 21 days post-dose
|
|
Incidence and severity of treatment-emergent adverse events (TEAEs)
大体时间:From first dose through 90 days after the last dose
|
The number and percentage of participants with TEAEs will be assessed. AEs will be graded according to NCI-CTCAE Version 6.0. |
From first dose through 90 days after the last dose
|
|
Incidence of serious adverse events (SAEs)
大体时间:From first dose through 90 days after the last dose
|
The number and percentage of participants with SAEs will be assessed. |
From first dose through 90 days after the last dose
|
|
Clinically significant changes in safety laboratory parameters from baseline
大体时间:From first dose through 90 days after the last dose
|
Clinically significant changes from baseline in safety laboratory parameters will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0 |
From first dose through 90 days after the last dose
|
|
Clinically significant changes in electrocardiogram (ECG) findings from baseline
大体时间:From first dose through 90 days after the last dose
|
Clinically significant changes from baseline in ECGs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0 |
From first dose through 90 days after the last dose
|
|
Clinically significant changes in vital signs from baseline
大体时间:From first dose through 90 days after the last dose
|
Clinically significant changes from baseline in vital signs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0. |
From first dose through 90 days after the last dose
|
|
Incidence of TEAEs leading to dose modifications
大体时间:From the first dose through the last dose; up to 1 year
|
The number and percentage of participants with TEAEs leading to CUG279 dose modification will be assessed. |
From the first dose through the last dose; up to 1 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Maximum observed plasma concentration (Cmax) of CUG279
大体时间:From first dose through 90 days after the last dose
|
The maximum observed plasma concentration (Cmax) of CUG279 will be determined from plasma concentration-time data |
From first dose through 90 days after the last dose
|
|
Trough plasma concentrations (Ctrough) of CUG279
大体时间:From first dose through 90 days after the last dose
|
The trough plasma concentration (Ctrough) of CUG279 will be determined from plasma samples collected immediately before the next scheduled dose |
From first dose through 90 days after the last dose
|
|
Area under the concentration-time curve (AUC) of CUG279
大体时间:From first dose through 90 days after the last dose
|
The area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-last) of CUG279 will be calculated using plasma concentration-time data. |
From first dose through 90 days after the last dose
|
|
Terminal half-life (T1/2) of CUG279
大体时间:From first dose through 90 days after the last dose
|
The terminal elimination half-life (t½) of CUG279 will be determined from plasma concentration-time data |
From first dose through 90 days after the last dose
|
|
Systemic clearance (CL) of CUG279
大体时间:From first dose through 90 days after the last dose
|
The systemic clearance (CL) of CUG279 will be determined from plasma concentration-time data |
From first dose through 90 days after the last dose
|
|
Volume of distribution (Vz) of CUG279
大体时间:From first dose through 90 days after the last dose
|
The volume of distribution (Vz) of CUG279 will be determined from plasma concentration-time data. |
From first dose through 90 days after the last dose
|
|
Incidence of anti-CUG279 antibodies (ADA)
大体时间:From first dose through 90 days after the last dose
|
Number and percentage of participants with treatment-emergent or treatment-enhanced anti-CUG279 antibodies will be determined. |
From first dose through 90 days after the last dose
|
|
Incidence of anti-CUG279 neutralizing antibodies (NAb)
大体时间:From first dose through 90 days after the last dose
|
Number and percentage of participants with neutralizing anti-CUG279 antibodies will be determined |
From first dose through 90 days after the last dose
|
|
Objective response rate (ORR)
大体时间:From the first dose through study completion or until disease progression; up to 1 year
|
Percentage of participants whose best overall response is a confirmed complete response (CR) or partial response (PR) will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Disease control rate (DCR)
大体时间:From the first dose through study completion or until disease progression; up to 1 year
|
Percentage of participants whose best overall response is CR, PR, or stable disease (SD) will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Time to response (TTR)
大体时间:From the first dose through study completion or until disease progression; up to 1 year
|
Time from the first dose of CUG279 to the first documented CR or PR will be determined, per RECIST v1.1 |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Duration of response (DoR)
大体时间:From the first dose through study completion or until disease progression; up to 1 year
|
Time from first documented CR or PR to disease progression will be determined per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Best overall response (BOR)
大体时间:From the first dose through study completion or until disease progression; up to 1 year
|
Best confirmed overall tumor response recorded from the first dose until disease progression or the end of efficacy assessment will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Progression-free survival (PFS)
大体时间:From the first dose through study completion or until disease progression; up to 1 year
|
Time from the first dose of CUG279 to radiographic disease progression will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.